For whom the T cells troll? Bispecific T-cell engagers in glioblastoma Singh, K, Hotchkiss, KM, Mohan, AA, Reedy, JL, Sampson, JH and Khasraw, Mustafa 2021, For whom the T cells troll? Bispecific T-cell engagers in glioblastoma, Journal for ImmunoTherapy of Cancer, vol. 9, no. 11, pp. 1-12, doi: 10.1136/jitc-2021-003679. Attached Files Name Description MIMEType Size Downloads Title For whom the T cells troll? Bispecific T-cell engagers in glioblastoma Author(s) Singh, K Hotchkiss, KM Mohan, AA Reedy, JL Sampson, JH Khasraw, Mustafa orcid.org/0000-0003-3249-9849 Journal name Journal for ImmunoTherapy of Cancer Volume number 9 Issue number 11 Article ID e003679 Start page 1 End page 12 Total pages 12 Publisher BMJ Place of publication London, Eng. Publication date 2021 ISSN 2051-1426 2051-1426 Keyword(s) ACUTE LYMPHOBLASTIC-LEUKEMIA ANTITUMOR-ACTIVITY BITE ANTIBODY BLOOD-BRAIN-BARRIER CD19 X CD3 central nervous system neoplasms HALF-LIFE IMMUNE CHECKPOINT Immunology immunotherapy Life Sciences & Biomedicine MALIGNANT GLIOMA MONOCLONAL-ANTIBODIES Oncology Science & Technology SINGLE-CHAIN ANTIBODY T lymphocytes Summary Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma. Obstacles to success include the heterogeneous tumor microenvironment (TME), the immune-privileged intracranial space, the blood–brain barrier (BBB) and local and systemic immunosuppressions. Monoclonal antibody-based therapies have failed at least in part due to their inability to access the intracranial compartment. Bispecific T-cell engagers are promising antibody fragment-based therapies which can bring T cells close to their target and capture them with a high binding affinity. They can redirect the entire repertoire of T cells against tumor, independent of T-cell receptor specificity. However, the multiple challenges posed by the TME, immune privilege and the BBB suggest that a single agent approach may be insufficient to yield durable, long-lasting antitumor efficacy. In this review, we discuss the mechanism of action of T-cell engagers, their preclinical and clinical developments to date. We also draw comparisons with other classes of multispecific antibodies and potential combinations using these antibody fragment therapies. Language eng DOI 10.1136/jitc-2021-003679 HERDC Research category C1 Refereed article in a scholarly journal Free to Read? Yes Persistent URL http://hdl.handle.net/10536/DRO/DU:30160469 Document type: Journal Article Collections: Faculty of Health School of Medicine Open Access Collection Related Links Link Description Link to full-text (Open access) Go to link with your DU access privileges   Connect to Elements publication management system Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au. Versions Version Filter Type Fri, 31 Dec 2021, 14:07:34 EST Fri, 31 Dec 2021, 14:51:59 EST Tue, 18 Jan 2022, 16:37:54 EST Wed, 23 Mar 2022, 14:07:13 EST Wed, 23 Mar 2022, 15:19:58 EST Wed, 23 Mar 2022, 15:31:28 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 0 times in Scopus Search Google Scholar Access Statistics: 6 Abstract Views, 0 File Downloads  -  Detailed Statistics Created: Fri, 31 Dec 2021, 14:07:34 EST